{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:14:10Z","timestamp":1783710850178,"version":"3.55.0"},"reference-count":34,"publisher":"Xia & He Publishing","issue":"000","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,9]]},"DOI":"10.14218\/jcth.2020.00150","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T23:14:43Z","timestamp":1617923683000},"page":"000-000","source":"Crossref","is-referenced-by-count":1,"title":["Effects of Bivalirudin and Unfractionated Heparin on Liver and Renal Function in Chinese Patients with Coronary Artery Disease Undergoing Coronary Angiography with\/without Percutaneous Coronary Intervention"],"prefix":"10.14218","volume":"000","author":[{"given":"Qiaowei","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzhi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"issue":"21","key":"key20210408231434_JCTH-D-20-00150-b1","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction","volume":"365","author":"Kastrati","year":"2011","journal-title":"N Engl J Med"},{"issue":"6 Pt 2","key":"key20210408231434_JCTH-D-20-00150-b2","doi-asserted-by":"crossref","first-page":"105S","DOI":"10.1592\/phco.22.10.105S.33616","article-title":"Clinical pharmacology of bivalirudin","volume":"22","author":"Reed","year":"2002","journal-title":"Pharmacotherapy"},{"issue":"3","key":"key20210408231434_JCTH-D-20-00150-b3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/CIRCINTERVENTIONS.113.001126","article-title":"Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry","volume":"7","author":"Bangalore","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"issue":"9","key":"key20210408231434_JCTH-D-20-00150-b4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcin.2011.05.022","article-title":"Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention","volume":"4","author":"Hanna","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"issue":"22","key":"key20210408231434_JCTH-D-20-00150-b5","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2011.08.051","article-title":"Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease","volume":"58","author":"Basra","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"key20210408231434_JCTH-D-20-00150-b6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0735-1097(02)01745-X","article-title":"The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions","volume":"39","author":"Best","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"key20210408231434_JCTH-D-20-00150-b7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0002-9149(03)00970-6","article-title":"Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials","volume":"92","author":"Chew","year":"2003","journal-title":"Am J Cardiol"},{"issue":"21","key":"key20210408231434_JCTH-D-20-00150-b8","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1161\/CIRCULATIONAHA.111.084996","article-title":"Antithrombotic therapy in patients with chronic kidney disease","volume":"125","author":"Capodanno","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"key20210408231434_JCTH-D-20-00150-b9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1525-139X.2006.00179.x","article-title":"Platelet dysfunction and end-stage renal disease","volume":"19","author":"Kaw","year":"2006","journal-title":"Semin Dial"},{"issue":"8","key":"key20210408231434_JCTH-D-20-00150-b10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/lt.25198","article-title":"Management of coagulation and anticoagulation in liver transplantation candidates","volume":"24","author":"Northup","year":"2018","journal-title":"Liver Transpl"},{"issue":"4","key":"key20210408231434_JCTH-D-20-00150-b11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"key20210408231434_JCTH-D-20-00150-b12","first-page":"ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","author":"Collet","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"key20210408231434_JCTH-D-20-00150-b13","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0002-9149(83)80105-2","article-title":"A more meaningful scoring system for determining the severity of coronary heart disease","volume":"51","author":"Gensini","year":"1983","journal-title":"Am J Cardiol"},{"issue":"1","key":"key20210408231434_JCTH-D-20-00150-b14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"9","key":"key20210408231434_JCTH-D-20-00150-b15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"8","key":"key20210408231434_JCTH-D-20-00150-b16","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.2337\/dc19-2137","article-title":"The impact of cardiovascular disease and chronic kidney disease on life expectancy and direct medical cost in a 10-year diabetes cohort study","volume":"43","author":"Wan","year":"2020","journal-title":"Diabetes Care"},{"key":"key20210408231434_JCTH-D-20-00150-b17","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/"},{"key":"key20210408231434_JCTH-D-20-00150-b18","volume-title":"Heparin Sodium, USP package insert","year":"2009"},{"issue":"5975","key":"key20210408231434_JCTH-D-20-00150-b19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/bmj.3.5975.77","article-title":"Hyper-transaminasemia with heparin therapy","volume":"3","author":"Sonnenblick","year":"1975","journal-title":"Br Med J"},{"issue":"5","key":"key20210408231434_JCTH-D-20-00150-b20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.7326\/0003-4819-100-5-646","article-title":"Transaminase elevations in patients receiving bovine or porcine heparin","volume":"100","author":"Dukes","year":"1984","journal-title":"Ann Intern Med"},{"issue":"4","key":"key20210408231434_JCTH-D-20-00150-b21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ajh.2830190406","article-title":"Complications of heparin administration in normal individuals","volume":"19","author":"Schwartz","year":"1985","journal-title":"Am J Hematol"},{"issue":"1","key":"key20210408231434_JCTH-D-20-00150-b22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1592\/phco.21.1.108.34436","article-title":"Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity","volume":"21","author":"Carlson","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"4","key":"key20210408231434_JCTH-D-20-00150-b23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1055\/s-2007-1002654","article-title":"Biologic tolerance of two different low molecular weight heparins","volume":"17","author":"Christiansen","year":"1991","journal-title":"Semin Thromb Hemost"},{"issue":"15","key":"key20210408231434_JCTH-D-20-00150-b24","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1161\/CIRCULATIONAHA.105.603100","article-title":"Anticoagulants and transaminase elevation","volume":"113","author":"Arora","year":"2006","journal-title":"Circulation"},{"issue":"1","key":"key20210408231434_JCTH-D-20-00150-b25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0169-6009(08)80078-5","article-title":"Effects of short-term low-dose heparin administration on biochemical parameters of bone turnover","volume":"22","author":"van der Wiel","year":"1993","journal-title":"Bone Miner"},{"issue":"7","key":"key20210408231434_JCTH-D-20-00150-b26","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1139\/o67-131","article-title":"Effects of heparin in vivo on lysosomal enzymes in rat plasma","volume":"45","author":"Levy","year":"1967","journal-title":"Can J Biochem"},{"issue":"2","key":"key20210408231434_JCTH-D-20-00150-b27","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/107602969800400209","article-title":"Transaminase Elevation in Patients Treated with Unfractionated Heparin or Low Molecular Weight Heparin for Venous Thromboembolism","volume":"4","author":"Girolami","year":"1998","journal-title":"Clin Appl Thrombo Hemost"},{"issue":"12","key":"key20210408231434_JCTH-D-20-00150-b28","first-page":"1133","article-title":"Hypertransaminasemia with subcutaneous heparin therapy","volume":"17","author":"Shilo","year":"1981","journal-title":"Isr J Med Sci"},{"issue":"2","key":"key20210408231434_JCTH-D-20-00150-b29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/clpt.2012.40","article-title":"The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers","volume":"92","author":"Harrill","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"key20210408231434_JCTH-D-20-00150-b30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5152\/tjg.2015.0086","article-title":"How to interpret liver function tests in heart failure patients?","volume":"26","author":"\u00c7a\u011fl\u0131","year":"2015","journal-title":"Turk J Gastroenterol"},{"issue":"3","key":"key20210408231434_JCTH-D-20-00150-b31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ijcard.2012.05.003","article-title":"Congestive hepatopathy and hypoxic hepatitis in heart failure: a cardiologist\u2019s point of view","volume":"166","author":"Kavoliuniene","year":"2013","journal-title":"Int J Cardiol"},{"issue":"36","key":"key20210408231434_JCTH-D-20-00150-b32","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1093\/eurheartj\/eht246","article-title":"Interactions of the heart and the liver","volume":"34","author":"M\u00f8ller","year":"2013","journal-title":"Eur Heart J"},{"issue":"3","key":"key20210408231434_JCTH-D-20-00150-b33","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1124\/jpet.105.087981","article-title":"Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine","volume":"314","author":"Luyendyk","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"key20210408231434_JCTH-D-20-00150-b34","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1097\/01.CCM.0000220764.10155.03","article-title":"Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats","volume":"34","author":"Harada","year":"2006","journal-title":"Crit Care Med"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2020-00150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:19:48Z","timestamp":1783707588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2020-00150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":34,"journal-issue":{"issue":"000","published-online":{"date-parts":[[2021,4,9]]},"published-print":{"date-parts":[[2021,4,9]]}},"alternative-id":["10.14218\/JCTH.2020.00150"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2020.00150","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]}}}